| 1. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Conditions: recurrent cutaneous T-cell lymphoma; recurrent mycosis fungoides/Sezary syndrome |
| 2. | | No longer recruiting | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult T-cell leukemia/lymphoma; angioimmunoblastic T-cell lymphoma; ... |
| 3. | | No longer recruiting | 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Colorectal Cancer
Conditions: recurrent colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; ... |
| 4. | | Completed | 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; recurrent adult acute myeloid leukemia; ... |
| 5. | | Recruiting | Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
Conditions: Breast Cancer; nausea and vomiting |
| 6. | | Recruiting | Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia |
| 7. | | No longer recruiting | Amifostine in Treating Patients With Myelodysplastic Syndrome
Conditions: Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; de novo myelodysplastic syndrome |
| 8. | | Recruiting | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
Conditions: adult solid tumor; Breast Cancer; Lung Cancer; neurotoxicity; ovarian epithelial cancer; Prostate Cancer |
| 9. | | Suspended | Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
Condition: Leukemia, Myelocytic, Acute |
| 10. | | No longer recruiting | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
Conditions: mucosa-associated lymphoid tissue; stage I diffuse small lymphocytic/marginal zone lymphoma |
| 11. | | Recruiting | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus; stage III esophageal cancer; stage IV esophageal cancer |
| 12. | | Completed | Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
Conditions: Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; refractory chronic myelogenous leukemia |
| 13. | | Completed | Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
Conditions: refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia |
| 14. | | Terminated | Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
Conditions: Squamous Cell Carcinoma; Head and Neck Neoplasms; Metastases, Neoplasm |
| 15. | | Recruiting | Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell |
| 16. | | No longer recruiting | Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer
Conditions: stage I prostate cancer; stage II prostate cancer; adenocarcinoma of the prostate |
| 17. | | Recruiting | Bevacizumab and PEG-Interferon alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: recurrent gastrointestinal carcinoid tumor; metastatic gastrointestinal carcinoid tumor; regional gastrointestinal carcinoid tumor |
| 18. | | Completed | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
Conditions: blastic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 19. | | Terminated | Blood Transplantation for Patients with Hematologic Malignancies or Bone Marrow Failure States
Conditions: Leukemia; Non Hodgkin's Lymphoma; Aplastic Anemia |
| 20. | | Completed | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Conditions: relapsing chronic myelogenous leukemia; recurrent adult acute myeloid leukemia; refractory anemia with excess blasts in transformation; ... |
| 21. | | No longer recruiting | BMS-214662 in Treating Patients With Solid Tumors
Conditions: unspecified childhood solid tumor, protocol specific; unspecified adult solid tumor, protocol specific |
| 22. | | No longer recruiting | Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Condition: refractory chronic lymphocytic leukemia |
| 23. | | No longer recruiting | Bone Marrow Transplantation in Treating Patients With Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; Waldenstrom's Macroglobulinemia; recurrent grade I follicular small cleaved cell lymphoma; ... |
| 24. | | Recruiting | Bortezomib and Mitoxantrone in Treating Patients With Advanced or Metastatic Androgen-Independent Prostate Cancer
Conditions: recurrent prostate cancer; stage III prostate cancer; stage IV prostate cancer |
| 25. | | Recruiting | Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Conditions: relapsing chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia; accelerated phase chronic myelogenous leukemia; ... |
| 26. | | Completed | Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult diffuse small cleaved cell lymphoma; ... |
| 27. | | Recruiting | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Conditions: Leukemia, Lymphocytic, Chronic; Leukemia, Lymphocytic, Acute; Lymphoma, Low-Grade; Lymphoma, T-Cell; Lymphoma, B-Cell |
| 28. | | Recruiting | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
Condition: Chronic Lymphocytic Leukemia |
| 29. | | Recruiting | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Conditions: stage II anal cancer; stage IIIA anal cancer; stage IIIB anal cancer; squamous cell carcinoma of the anus |
| 30. | | Recruiting | CC-5013 in Myelofibrosis
Condition: Myelofibrosis |
| 31. | | Recruiting | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer; ... |
| 32. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; childhood acute myeloid leukemia and other myeloid malignancies; ... |
| 33. | | Recruiting | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: refractory chronic lymphocytic leukemia; recurrent adult diffuse large cell lymphoma; recurrent adult Hodgkin's lymphoma |
| 34. | | Terminated | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
Conditions: Chronic Myelogenous Leukemia; Multiple Myeloma; Non Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia |
| 35. | | Not yet recruiting | Celecoxib and/or EKB-569 in Preventing Oral Cancer in Patients With Oral Leukoplakia
Conditions: lip and oral cavity cancer; Salivary Gland Cancer; Precancerous Condition |
| 36. | | Recruiting | Celecoxib in Treating Patients With Bladder Cancer
Condition: recurrent bladder cancer |
| 37. | | Recruiting | Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis.
Conditions: Colon Cancer; Rectal Cancer |
| 38. | | No longer recruiting | Chemoprevention Therapy Plus Surgery in Treating Patients With Breast Cancer
Conditions: stage I breast cancer; ductal breast carcinoma; invasive ductal breast carcinoma; prevention of breast cancer; stage II breast cancer |
| 39. | | No longer recruiting | Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Philadelphia chromosome positive chronic myelogenous leukemia; chronic phase chronic myelogenous leukemia |
| 40. | | No longer recruiting | Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
Conditions: advanced adult primary liver cancer; liver metastases; adult primary hepatocellular carcinoma; localized unresectable adult primary liver cancer |
| 41. | | No longer recruiting | Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Conditions: adenocarcinoma of the prostate; stage III prostate cancer; stage IV prostate cancer; recurrent prostate cancer |
| 42. | | No longer recruiting | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Conditions: Leukemia, Myeloid; Leukemia, Myeloid, Chronic |
| 43. | | Recruiting | Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Conditions: adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer |
| 44. | | Recruiting | Chemotherapy, Interferon alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
Conditions: stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; adenocarcinoma of the pancreas |
| 45. | | No longer recruiting | Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: Leukemia; Lymphoma; Multiple Myeloma; Eye Cancer |
| 46. | | Recruiting | Cilengitide in Treating Patients With Acute Myeloid Leukemia
Conditions: adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia |
| 47. | | Recruiting | Cilengitide in Treating Patients With Metastatic Melanoma
Condition: Stage IV Melanoma |
| 48. | | No longer recruiting | Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer |
| 49. | | Recruiting | Clofarabine alone versus Clofarabine in Combination with Low-Dose Cytarabine (ara-C) in Previously Untreated Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome |
| 50. | | Recruiting | Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia |
